{"id":"golimumab-injection","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Injection site reactions"},{"rate":"10-15","effect":"Upper respiratory tract infections"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"1-3","effect":"Increased infection risk (serious infections)"},{"rate":"<1","effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL1201833","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF-α is a key pro-inflammatory cytokine that drives immune-mediated inflammation in autoimmune and inflammatory diseases. By neutralizing TNF-α, golimumab suppresses the inflammatory cascade and reduces disease activity. This mechanism is effective across multiple TNF-driven conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease.","oneSentence":"Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:09.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT05071664","phase":"PHASE2","title":"A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-25","conditions":"Arthritis, Psoriatic","enrollment":91},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT05669833","phase":"PHASE3","title":"Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-14","conditions":"Psoriatic Arthritis","enrollment":63},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT03733925","phase":"PHASE4","title":"A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2019-01-07","conditions":"Spondylitis, Ankylosing, Arthritis, Psoriatic","enrollment":100},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT05842213","phase":"PHASE3","title":"Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2023-03-30","conditions":"Rheumatoid Arthritis","enrollment":502},{"nctId":"NCT03557853","phase":"","title":"Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab","status":"COMPLETED","sponsor":"MSD Pharmaceuticals LLC","startDate":"2016-06","conditions":"Ankylosing Spondylitis, Coxitis","enrollment":39},{"nctId":"NCT04152759","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2019-09-09","conditions":"Psoriatic Arthritis","enrollment":182},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT05332730","phase":"PHASE1","title":"A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-08-01","conditions":"Psoriatic Arthritis","enrollment":375},{"nctId":"NCT03253796","phase":"PHASE4","title":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-07","conditions":"Spondyloarthritis","enrollment":323},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT04200833","phase":"","title":"Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-03-01","conditions":"JIA Associated Uveitis","enrollment":10},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT03955861","phase":"","title":"Ultrasound Enthesitis Response in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-02-14","conditions":"Psoriatic Arthritis, Psoriasis, Enthesitis","enrollment":80},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT01610947","phase":"NA","title":"Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-05-14","conditions":"Spondyloarthritis","enrollment":398},{"nctId":"NCT02318667","phase":"PHASE4","title":"Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Colitis, Ulcerative","enrollment":38},{"nctId":"NCT02011386","phase":"","title":"Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Professor Mikkel Østergaard","startDate":"2013-02","conditions":"Axial Spondyloarthritis","enrollment":53},{"nctId":"NCT02841176","phase":"NA","title":"Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis","status":"TERMINATED","sponsor":"Imperial College Healthcare NHS Trust","startDate":"2016-07","conditions":"Psoriatic Arthritis","enrollment":4},{"nctId":"NCT02155335","phase":"PHASE4","title":"Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-07-01","conditions":"Ulcerative Colitis","enrollment":100},{"nctId":"NCT02092285","phase":"PHASE4","title":"Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-09","conditions":"Ulcerative Colitis","enrollment":205},{"nctId":"NCT01453725","phase":"PHASE3","title":"Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-13","conditions":"Spondylitis, Ankylosing","enrollment":198},{"nctId":"NCT01871649","phase":"PHASE3","title":"Initial Treatment With Golimumab in Early PsA","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-08","conditions":"Psoriatic Arthritis","enrollment":51},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT02910375","phase":"PHASE4","title":"Golimumab Dried Blood Spot Analysis","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-12","conditions":"Ulcerative Colitis","enrollment":10},{"nctId":"NCT01362153","phase":"PHASE1","title":"A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-12-26","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT01217814","phase":"PHASE2","title":"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT01863771","phase":"PHASE3","title":"A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-03-15","conditions":"Colitis, Ulcerative","enrollment":144},{"nctId":"NCT01988961","phase":"PHASE2","title":"A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-12","conditions":"Colitis, Ulcerative","enrollment":103},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT01313858","phase":"","title":"A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing","enrollment":1613},{"nctId":"NCT01715896","phase":"PHASE2","title":"A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":215},{"nctId":"NCT00488631","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-09","conditions":"Colitis, Ulcerative","enrollment":1228},{"nctId":"NCT01230827","phase":"PHASE3","title":"A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Juvenile Idiopathic Arthritis","enrollment":173},{"nctId":"NCT01692457","phase":"","title":"A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica","startDate":"2013-07","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis","enrollment":""},{"nctId":"NCT00771251","phase":"PHASE3","title":"A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":311},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00675649","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma","status":"WITHDRAWN","sponsor":"Centocor, Inc.","startDate":"2008-05","conditions":"Asthma","enrollment":""},{"nctId":"NCT00264537","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":637},{"nctId":"NCT00361335","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":643},{"nctId":"NCT00264550","phase":"PHASE3","title":"An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Rheumatoid Arthritis","enrollment":444},{"nctId":"NCT00299546","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-02","conditions":"Arthritis, Rheumatoid","enrollment":461},{"nctId":"NCT00487539","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-08","conditions":"Colitis, Ulcerative","enrollment":1065},{"nctId":"NCT01526174","phase":"PHASE1, PHASE2","title":"Intratympanic Injection for Autoimmune Inner Ear Disease","status":"TERMINATED","sponsor":"House Research Institute","startDate":"2012-03","conditions":"Autoimmune Inner Ear Disease","enrollment":16},{"nctId":"NCT01248780","phase":"PHASE3","title":"Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":264},{"nctId":"NCT00265083","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Spondylitis, Ankylosing","enrollment":356},{"nctId":"NCT00265096","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2005-12","conditions":"Arthritis, Psoriatic","enrollment":407},{"nctId":"NCT00727987","phase":"PHASE3","title":"A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-05","conditions":"Rheumatoid Arthritis","enrollment":269},{"nctId":"NCT01248793","phase":"PHASE3","title":"Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2010-10","conditions":"Ankylosing Spondylitis","enrollment":213},{"nctId":"NCT00207714","phase":"PHASE2","title":"An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Rheumatoid Arthritis","enrollment":172},{"nctId":"NCT00207740","phase":"PHASE2","title":"A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-08","conditions":"Asthma","enrollment":309}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"LIMB MASS"},{"count":1,"reaction":"NEOPLASM SKIN"},{"count":1,"reaction":"PAIN"},{"count":1,"reaction":"SWOLLEN TONGUE"}],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Based on decision of investigators."],"phase":"phase_3","status":"active","brandName":"Golimumab Injection","genericName":"Golimumab Injection","companyName":"MSD Pharmaceuticals LLC","companyId":"msd-pharmaceuticals-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}